Physician profile
Robert S Dye
NPI 1215095179
$7,786.09
in general payments reported to CMS, 2019-2025
36 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $425 · 2021: $601 · 2022: $1,238 · 2023: $1,462 · 2024: $791 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Education: $9.65 · Travel and Lodging: $6.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,527.34 |
| Education | $9.65 |
| Travel and Lodging | $6.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,637.79 | 2019-2023 | |
| Allergan, INC. | $990.26 | 2019-2022 | |
| Abbvie INC. | $981.42 | 2021-2025 | Botox, Skyrizi |
| Sun Pharmaceutical Industries INC. | $520.73 | 2019-2024 | Winlevi, Odomzo, Blu-U |
| Janssen Biotech, INC. | $467.88 | 2020-2025 | Tremfya |
| Galderma Laboratories, L.P. | $408.72 | 2019-2025 | Aklief, Oracea, Dysport |
| Amgen INC. | $401.31 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $302.99 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Revance Therapeutics, INC. | $239.23 | 2024-2025 | Daxxify, Daxi |
| Ucb, INC. | $230.08 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $199.39 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $178.26 | 2021-2024 | |
| Organogenesis INC. | $155.33 | 2024-2025 | Cygnus Dual |
| Biofrontera INC. | $118.78 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $112.24 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $110.34 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $104.74 | 2023-2024 | Zoryve |
| Pfizer INC. | $102.48 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $83.73 | 2025 | Libtayo |
| Botanix Sb INC | $41.61 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $41.28 | 2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.63 | 2020-2025 | Cabtreo, Jublia, Siliq |
| Celgene Corporation | $34.18 | 2019 | |
| Prugen, INC. Pharmaceuticals | $33.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.19 | 2022 | |
| Medtronic Vascular, INC. | $28.96 | 2020 | |
| Boston Scientific Corporation | $24.83 | 2025 | Varithena Administration Pack |
| Sanofi-Aventis U.S. LLC | $24.11 | 2019 | |
| Epi Health, LLC | $22.30 | 2022 | |
| Vyne Pharmaceuticals INC. | $21.06 | 2020 | |
| Mission Pharmacal Company | $20.06 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.00 | 2019 | |
| Sandoz INC. | $16.96 | 2019 | |
| Mayne Pharma Commercial LLC | $14.52 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $14.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.